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Purpose: This study aimed to evaluate the non-inferiority of initiating extrafine beclome-
tasone dipropionate/formoterol fumarate (BDP/FF) versus double bronchodilation (long- 
acting beta-agonists [LABA]/long-acting muscarinic antagonists [LAMA]) among patients 
with a history of chronic obstructive pulmonary disease (COPD) exacerbations.
Patients and Methods: A historical cohort study was conducted using data from the UK’s 
Optimum Patient Care Research Database. Patients with COPD ≥40 years at diagnosis were 
included if they initiated extrafine BDP/FF or any LABA/LAMA double therapy as a step-up 
from no maintenance therapy or monotherapy with inhaled corticosteroids (ICS), LAMA, or LABA 
and a history of ≥2 moderate/severe exacerbations in the previous two years. The primary outcome 
was exacerbation rate from therapy initiation until a relevant therapy change or end of follow-up. 
Secondary outcomes included rate of acute respiratory events, acute oral corticosteroids (OCS) 
courses, and antibiotic prescriptions with lower respiratory indication, modified Medical Research 
Council score (mMRC) ≥2, and time to first pneumonia diagnosis. The non-inferiority boundary 
was set at a relative difference of 15% on the ratio scale. Five potential treatment effect modifiers 
were investigated.
Results: A total of 1735 patients initiated extrafine BDP/FF and 2450 patients initiated LABA/ 
LAMA. The mean age was 70 years, 51% were male, 41% current smokers, and 85% had FEV1 
<80% predicted. Extrafine BDP/FF showed non-inferiority to LABA/LAMA for rate of exacer-
bations (incidence rate ratio [IRR] = 1.01 [95% CI 0.94–1.09]), acute respiratory events (IRR = 
0.98 [0.92–1.04]), acute OCS courses (IRR = 1.01 [0.91–1.11]), and antibiotic prescriptions (IRR 
= 0.99 [0.90–1.09]), but not for mMRC (OR = 0.93 [0.69–1.27]) or risk of pneumonia (HR = 0.50 
[0.14–1.73]). None of the a priori defined effect modifier candidates affected the comparative 
effectiveness.
Conclusion: This study found that stepping up to extrafine BDP/FF from no maintenance or 
monotherapy was not inferior to stepping up to double bronchodilation therapy in patients 
with a history of exacerbations.
Keywords: real-world, electronic health records, observational, comparative effectiveness, 
heterogeneity, chronic obstructive pulmonary disease
Introduction
The aim of chronic obstructive pulmonary disease (COPD) treatment is to reduce 
symptoms and the frequency and severity of exacerbations, and to improve health 
status and exercise tolerance. Long-acting bronchodilators (long-acting muscarinic 
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antagonists [LAMAs] and long-acting beta-agonists 
[LABAs]) are the mainstay of therapeutic management 
for COPD; their combined use can result in greater bene-
fits than from either therapy alone.1–5 Inhaled corticoster-
oids (ICS)/LABA combinations are also more effective 
than each component alone, especially for exacerbation 
prevention.6 Furthermore, higher blood eosinophil counts 
is a biomarker associated with an increased benefit from 
ICS.7 Therefore, in the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) 2020 recommenda-
tions, ICS/LABA is indicated as a step-up from broncho-
dilator monotherapy for exacerbating patients (at least two 
moderate or one severe exacerbation in the previous year) 
with a blood eosinophil count above 100 cells/µL.8 
However, these recommendations are solely based on 
insights obtained from randomized clinical trials. The real- 
world evidence on the effectiveness of ICS/LABA in such 
patients compared with other treatment combinations 
remains limited. Since patients in randomized trials are 
not necessarily representative of the patients with COPD 
in real life, we need real-world evidence added to the trial 
insights to ensure optimal disease management 
recommendations.
The FLAME study showed that indacaterol/glycopyr-
ronium (LABA/LAMA) was more effective than flutica-
sone/salmeterol in exacerbation prevention in patients with 
a history of exacerbations.9 Only 19.3% of patients in the 
FLAME study however, had a history of two or more 
moderate to severe exacerbations in the previous year. In 
another trial (IMPACT), different results were reported 
regarding the respective efficacy of these two therapeutic 
options.10 This discrepancy could relate to variations in 
study populations (over 50% of the patients included in the 
IMPACT study had two or more exacerbations) and/or 
previous treatment history. The abrupt withdrawal of ster-
oids in patients assigned to the LABA/LAMA arm, in 
addition to the inclusion of patients with asthma in the 
IMPACT trial, likely contributed to the rapid increase in 
exacerbations seen in the LABA/LAMA arm.11
Extrafine formulations of inhaled treatments increase 
drug delivery to the small airways,12 which may improve 
the benefit of ICS for exacerbation prevention in COPD, 
where small airway inflammation is prominent. A unique 
feature of extrafine beclometasone dipropionate/formoterol 
fumarate (BDP/FF) combination in a single inhaler is that 
it may be associated with increased effectiveness13 and 
lower risk of pneumonia.14 There are no real-world evi-
dence studies on the comparative effectiveness of initiating 
a fixed-dose combination of extrafine BDP/FF in a single 
inhaler versus LABA/LAMA.
We aimed to determine whether initiating treatment 
with an extrafine BDP/FF combination in a single inhaler 
was at least as effective as double bronchodilator therapy 
(LABA/LAMA) in terms of reducing COPD exacerbations 
in patients with COPD and a history of exacerbations in 
a historical cohort extracted from 2002 to 2019. Several 
patient characteristics have been identified before as risk 
factors for disease severity.15–17 Therefore, we also aimed 
to determine how the comparative effectiveness was mod-
ified by the exacerbation burden in the baseline year, most 
recent blood eosinophil count, degree of airflow limitation, 
COPD GOLD group, and number of concomitant drugs 
prescribed in the baseline year.
Materials and Methods
Study Design and Data Source
This was a historical cohort study comparing patients with 
COPD and a history of exacerbations who initiated extra-
fine BDP/FF (ICS/LABA) to those who initiated LABA/ 
LAMA double therapy in the United Kingdom (UK; 
Figure 1). The index date, which was the date of therapy 
initiation, separated a one-year baseline period and the 
outcome period. Data were extracted for patients who 
stepped up to extrafine BDP/FF or LABA/LAMA from 
either no maintenance therapy, or monotherapy with ICS, 
LAMA, or LABA between 2002 and 2019. The study used 
primary care data from the Optimum Patient Care 
Research Database (OPCRD; https://opcrd.co.uk/). 
OPCRD contains anonymized, longitudinal medical record 
data for over eight million patients from over 700 primary 
care practices. The median follow-up duration of medical 
records is 13 years. These data contain information on 
demographic and lifestyle parameters, clinical events, 
referrals to and feedback from specialists, and prescrip-
tions. It is a high-quality data source used regularly in 
clinical, epidemiological, and pharmaceutical 
research.18,19 OPCRD is approved by the Health 
Research Authority for clinical research use and governed 
by the Anonymised Data Ethics & Protocol Transparency 
(ADEPT) Committee, an independent body of experts and 
regulators commissioned by the Respiratory Effectiveness 
Group (REG, http://www.effectivenessevaluation.org/). 
This study was approved by the ADEPT committee 
(approval reference ADEPT0419).
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Study Population
Patients were included in the study if they met the following 
criteria: 1) initiated extrafine fixed dose combination ICS/ 
LABA (extrafine BDP/FF) or any LABA/LAMA double 
therapy, either as a fixed-dose combination or two separate 
inhalers, as a step-up from no maintenance therapy or 
monotherapy with ICS, LAMA, or LABA; 2) received the 
initiated therapy for at least 90 days (to avoid the inclusion 
of artefacts, temporary medical records, and temporary 
interruption of one medication class); 3) had a diagnostic 
Read code for COPD, not followed by a COPD “resolved” 
code; 4) were aged ≥40 years at index date; 5) had at least 
one year of continuous practice data prior to the index date 
(baseline year); and 6) had two or more moderate/severe 
exacerbations (see Table 1 for definition) in the two years 
prior to and including the index date. With this 2-year 
period we optimize the use of available longitudinal data, 
resulting in greater ability to assess effect modification by 
exacerbation burden.
Patients who had active asthma at or after the index 
date (defined as ≥1 diagnostic Read code for asthma or ≥1 
asthma monitoring or review Read code recorded), a Read 
code for Asthma-COPD overlap syndrome as the COPD 
diagnostic code, a diagnostic code for other chronic lower 
respiratory conditions ever recorded, or no evidence of 
smoking ever were excluded from the analyses. All code 
lists are available from the authors upon request. Code lists 
for COPD and asthma were based on version 38 of the 
Quality and Outcomes Framework business rules, a pay- 
for-performance scheme active in the UK since 2004, 
Index Date
First prescription of Extrafine BDP/FF or 
LABA/LAMA
Age ≥ 40 years
Day 0
Eligibility Window 1





Rates assessment, time to event Window
Days [1, Censor]





COPD diagnosis, NOT ACOS
Days [∞,-1]
Eligibility Window 2





≥ 1 year of continuous practice data
Days [-365,-1]
Eligibility Window 5






No other chronic lower respiratory conditions; evidence of smoking
Days [∞,∞]
Blood eosinophil count assessment Window
Last value
Days [-1826,-1]
Figure 1 Study design. 
Abbreviations: COPD, chronic obstructive pulmonary disease; extrafine BDP/FF, extrafine beclometasone dipropionate/formoterol fumarate; LABA, long-acting beta- 
agonist; LAMA, long-acting muscarinic antagonist; ACOS, asthma-COPD overlap syndrome; mMRC, Modified Medical Research Council Dyspnea Scale.
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which has resulted in highly accurate recording of 
diagnoses.20 In line with a recently suggested framework 
of graphical representation of studies done in health care 
databases,21 we provide such detailed information in 
Figure 1.
Patients were divided into two exposure groups: those 
who initiated extrafine BDP/FF in a single inhaler and 
those who initiated LABA/LAMA. Where a patient was 
eligible for both groups, the LABA/LAMA initiation date 
was used, to avoid a patient being used twice in the 
analyses. Where multiple initiation dates of the same 
drug group occurred, the first date was used as the index 
date in the analyses.
Study Outcomes
The primary outcome was the annualized rate of moderate/ 
severe COPD exacerbations (see Table 1 for definition) 
during follow-up. Follow-up began on the index date (ie 
therapy initiation) and continued until the patient left the 
practice, had a relevant therapy change, or until the last 
date of the practice’s data collection. In the extrafine BDP/ 
FF group, a relevant therapy change comprised a switch to 
triple therapy (ICS/LABA/LAMA), a switch to another 
ICS/LABA, or a switch to no maintenance therapy, 
LAMA or LABA monotherapy, or LABA/LAMA double 
therapy when extrafine BDP/FF was not switched back to 
within six months. This tolerance period of six months was 
used to avoid exposure misclassification due to apparent 
small changes in therapy which could be the result of 
artefacts in the data. In the LABA/LAMA group, 
a relevant therapy change comprised a switch to an ICS- 
containing therapy or a switch to no maintenance therapy 
or LAMA or LABA monotherapy when LABA/LAMA 
was not switched back to within six months. The second-
ary outcomes were rate of acute respiratory events, acute 
oral corticosteroids courses, and antibiotic prescriptions 
with lower respiratory indication, modified Medical 
Research Council score (mMRC) within 18 months after 
index date, and time to first pneumonia diagnosis. Details 
on the primary and secondary outcomes are presented in 
Table 1.
Data Analyses
Analyses were performed using Stata MP/6 version 15.1 
(StataCorp, College Station, TX). The type and duration of 
prior maintenance therapies were assessed for all patients 
included.
Continuous variables were summarized using descrip-
tive statistics of central tendency (mean and median) and 
dispersion (standard deviation [SD] and interquartile range 
[IQR]). Categorical variables were described with frequen-
cies and percentages. The standardized mean difference 
(SMD) was used to quantify differences in both continu-
ous and categorical variables between the groups at base-
line. We considered an SMD ≤10% to indicate sufficient 
balance between the groups.
Table 1 Study Outcomes and Definitions
Outcome Definitions
Primary Rate of moderate/severe COPD exacerbations during 
the entire follow-up (ie until end of data availability or 
censoring due to a relevant therapy change) defined as:
● Respiratory-related hospital attendance/admission 
(based on GP medical record data) AND/OR,
● Respiratory-related A&E attendance (based on GP 
medical record data) AND/OR,
● Acute OCS course prescription AND/OR,
● Antibiotics prescribed with evidence of a lower 
respiratory consultation on the same day.
Events occurring within 14 days of a previous event 
were considered part of the same episode. 
A relevant therapy change was either discontinua-
tion of the index therapy or additional medication.
Secondary Rate of occurrences during the entire follow-up of:
1. Acute respiratory events (defined as a moderate/severe 
exacerbation or an unplanned respiratory-related con-
sultation, not for annual monitoring/review).
2. Acute OCS courses.
3. Antibiotic prescriptions with evidence of lower 
respiratory consultation.
4. mMRC score within 18 months after index date 
(≥2 vs ≤2).
5. Time to first pneumonia diagnosis (diagnostic code 
with a code for a chest X-ray within 30 days around 
the date).
6. Treatment failure (defined as the occurrence of 
a moderate/severe exacerbation, prescription of addi-
tional chronic COPD therapy, or a step-up to triple 
therapy after the index date). This was an a priori 
secondary outcome, but not included for the purpose 
of this paper as the reasons for treatment failure were 
very different between the study arms, and we there-
fore judged it to be a poor indicator of treatment 
effectiveness.
Events occurring within 14 days of a previous event 
were considered part of the same episode.
Abbreviations: COPD, chronic obstructive pulmonary disease; GP, general prac-
tice; mMRC, Modified Medical Research Council Dyspnea Scale; OCS, oral 
corticosteroid.
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Inverse probability of treatment (IPT) weighting was 
used to account for potential biases such as indication bias, 
as attempts to match the study groups resulted in 29–50% 
loss in patient numbers and selection of less severely ill 
patients. A propensity score was generated with a logistic 
regression model using all available baseline characteris-
tics which had shown an association to the outcome of 
interest. The propensity score was used to weight the data 
with the inverse of the treatment probability. Weights 
above the 99th percentile and below the 1st percentile 
were truncated at these values. Weighted SMDs were 
calculated to verify the balancing effect of the IPT weight-
ing approach.
The number of patients who improved (ie, fewer num-
ber of exacerbations in the one-year follow-up period 
compared to the baseline period), remained stable (same 
number), and worsened (more in the one-year follow-up 
period than the baseline period) was calculated in those 
patients with at least one year of follow-up. Unadjusted 
and IPT weighted changes are reported.
Non-inferiority of initiating extrafine BDP/FF versus 
double bronchodilators was tested in per protocol analyses. 
The upper boundary of non-inferiority was set at a relative 
difference of 15% (corresponding to a hazard ratio [HR], 
incidence rate ratio [IRR], or odds ratio [OR] for outcomes 
with extrafine BDP/FF versus LABA/LAMA of 1.15) 
based on clinical and statistical considerations. The margin 
was defined on the limit of the 95% confidence interval 
that is closest to the null effect.22 Clinical judgement was 
applied to choose the fraction of the null effect that must 
be preserved by the active drug, in this case 50%. Event 
rates over the entire follow-up period were analyzed using 
conditional negative binomial regression, weighted by the 
logarithm of the duration of follow-up to account for 
differences in length of follow-up between patients and 
adjusted for covariates that caused a change in estimate of 
>2% in the IPT weighted analyses. Given the number of 
extrafine BDP/FF and LABA/LAMA initiators in this 
study, there was 90% power, using 5% significance, to 
detect a minimal difference in exacerbation rate of 10%. 
Time-to-event analyses were used to analyze the associa-
tion between treatment and time to first pneumonia diag-
nosis with right censoring at the time of loss to follow-up 
or treatment change, adjusted for residual confounders 
following IPT weighting. To account for multiple testing, 
Holm’s method23 was used to adjust significance levels for 
the six primary and secondary outcomes. Patients with 
a history of asthma and/or a diagnosis of allergic rhinitis 
were excluded in sensitivity analyses to assess the robust-
ness of the findings with regards to incomplete exclusion 
of patients with concomitant asthma.
Effect modification was assessed for the following five 
candidates: exacerbation burden in the baseline year, most 
recent blood eosinophil count (within five years), degree 
of airflow limitation (FEV1% predicted), COPD GOLD 
group (A-D), and number of distinct drugs (apart from 
COPD drugs) prescribed in the baseline year. Effect mod-
ification was tested by introducing an interaction term 
between exposure and the candidate modifier into the 
regression models. Significance levels for the interaction 
terms were adjusted using Holm’s method.
The study population was created in 2018, and thus 
a large majority of patients had their index date before the 
changes in COPD treatment recommendations after 2018. 
More specifically, the 2019 GOLD Report version recom-
mended incorporating the use of peripheral blood eosino-
phil counts to predict the efficacy of ICS for exacerbation 
prevention.8 Therefore, we further assessed the effect of 
blood eosinophil count on the comparative effectiveness, 
as post hoc analyses, in the following COPD subgroups: a) 
patients with ≥1 severe or ≥2 moderate exacerbations in 
the one-year baseline period (1597 LABA/LAMA and 
1244 extrafineBDP/FF initiators), b) patients with ≥3 mod-
erate/severe exacerbations in the one-year baseline period 
(734 LABA/LAMA and 681 extrafine BDP/FF initiators), 
and c) patients who stepped up from either LAMA or 
LABA monotherapy (669 LABA/LAMA and 283 extra-
fine BDP/FF initiators). Please refer to the online 
Supplementary Materials for further details regarding 
methodology.
Role of the Funding Source
The funder of the study participated in the study design. 
All authors, including those employed by the funder of the 
study, participated in the data interpretation, and writing of 
the manuscript. All authors had full access to study results 
and had final responsibility for the decision to submit for 
publication.
Results
A total of 1735 eligible patients initiated extrafine BDP/FF 
and 2450 patients initiated LABA/LAMA. A patient flow 
chart is displayed in Figure 2. Weighted summary statistics 
of demographic and clinical characteristics of patients who 
initiated extrafine BDP/FF and those who initiated LABA/ 
LAMA are presented in Table 2 (and Table e1 in the 
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Online Supplementary Materials). Ninety-four percent (73/ 
78) of characteristics were well balanced (SMD≤10%) 
between treatment groups following weighting. The mean 
age in both groups was 70 years and around half of 
patients were male. Over 30% of patients in both groups 
belonged to GOLD group D at baseline. Unweighted base-
line characteristics are presented in supplementary Table 
e2. Notably, in the baseline year a higher percentage of 
extrafine BPD/FF initiators experienced from 3 to >5 
exacerbations (43.6%) in comparison to LABA/LAMA 
initiators (33.9%). In the meantime, a higher percentage 
of LABA/LAMA initiators experienced from 0 to 2 
exacerbations (66.1%) in comparison to extrafine BDP/ 
FF initiators (56.6%). This imbalance was confirmed by 
the standardized mean difference of 23.8.
The duration of therapies prior to the index date and 
the time patients stayed on the index therapy was similar 
between patients who initiated extrafine BDP/FF and those 
who initiated LABA/LAMA. Approximately 38% of 
patients in each group received refill prescriptions for 
their index therapy for at least one year. The duration of 
follow-up was 1.5 years for both groups.
The number of patients who improved, remained 
stable, or worsened from the baseline year to the first 
follow-up year for each outcome variable is displayed in 
Table 3. Both treatment groups showed a reduction in the 
number of exacerbations from the baseline to the 
outcome year (61% of extrafine BDP/FF and 58% of 
LABA/LAMA initiators). The percentage of extrafine 
BDP/FF initiators who worsened was 21.5% compared to 
23.5% of LABA/LAMA initiators (Table 3).
Multivariable Outcome Models
Extrafine BDP/FF was non-inferior to LABA/LAMA for the 
primary outcome in the weighted model; the upper confidence 
limit for exacerbation rate of 1.09 was below the prespecified 
non-inferiority margin of 1.15 (IRR = 1.01 [95% CI 0.94–-
1.09]; Figure 3). Extrafine BDP/FF was also non-inferior to 
LABA/LAMA for secondary outcomes including rate of acute 
respiratory events (IRR = 0.98 [0.92–1.04]), acute OCS 
courses (IRR = 1.01 [0.91–1.11]), and antibiotic prescriptions 
with evidence of lower respiratory indication (IRR = 0.99 
[0.90–1.09]; Figure 3). However, non-inferiority was not 
achieved for the secondary outcomes of having an mMRC 
score ≥2 (HR = 0.96 [0.74–1.23]) and risk of a pneumonia 
infection (HR = 0.50 [0.14–1.73]). See Table e3 in the Online 
Supplementary Materials for unadjusted data on follow-up and 
outcomes. Results were similar when patients with a history of 
asthma and/or rhinitis were excluded in sensitivity analyses 
(see Figure e1 in the Online Supplementary Materials).
Effect Modification
There was no evidence that any of the a priori candidate 
modifiers (blood eosinophil count, exacerbations, GOLD 
group, FEV1% predicted, other medication burden) signifi-
cantly changed the comparative effectiveness between 
Excluded (F=17,845, L=16,009)
• Persistence <90 days (F=8,680, L=9,035)
• Age <40 (F=17, L=6)
• <1 year of medical record data available 
before index date (F=1,164, L=761)
• <2 exacerbations in a 2-year period 
before and including the index date 
(F=4,049, L=5,059)
• Active asthma (F=1,456, L=386)
• ACOS (F=7, L=3)
• Other chronic lower respiratory 
conditions (F=203, L=177)
• No evidence of smoking ever (F=107, 
L=52)
• Prior therapy not no maintenance, or 
LAMA, LABA or ICS monotherapy 
(L=2,162, F=483)
• Duplicates (L=47)
BDP/FF initiators = 19,580
LABA/LAMA initiators = 18,459
Included:
BDP/FF initiators = 1,735
LABA/LAMA initiators = 2,450
Figure 2 Patient flowchart. 
Abbreviations: ACOS, asthma-COPD overlap syndrome; LAMA, long-acting muscarinic antagonist; LABA, long-acting beta-agonist; ICS, inhaled corticosteroids; Extrafine 
BDP/FF, extrafine Beclometasone dipropionate/formoterol fumarate.
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Table 2 Baseline Characterization of IPT Weighted Population
Variable LABA/LAMA (N=2450) Extrafine BDP/FF (N=1735) SMD
Age (years) Mean (SD) 70.4 (10.0) 69.8 (10.5) 1.9
Male gender n (%) 1299 (53.0) 822 (47.4) 2.7
Smoking status Current, n (%) 1044 (42.6) 677 (39.0) 0.8
Former, n (%) 1389 (56.7) 1052 (60.6)
Missing, n (%) 17 (0.7) 6 (0.3)
BMI (kg/m2) <18.5, n (%) 115 (4.7) 78 (4.5) 1.2
≥18.5 <25, n (%) 750 (30.6) 525 (30.3)
≥25 <30, n (%) 764 (31.2) 555 (32.0)
≥30, n (%) 713 (29.1) 510 (29.4)
Missing, n (%) 108 (4.4) 67 (3.9)
Asthma diagnosis ever n (%) 481 (19.6) 496 (28.6) 0.7
Eosinophil count (109/L) <0.05, n (%) 80 (3.3) 67 (3.9) 1.9
0.05 <0.15, n (%) 593 (24.2) 407 (23.5)
0.15 <0.25, n (%) 682 (27.8) 455 (26.2)
0.25 <0.35, n (%) 396 (16.2) 288 (16.6)
0.35 <0.45, n (%) 180 (7.3) 147 (8.5)
0.45 <0.55, n (%) 95 (3.9) 84 (4.8)
0.55 <0.65, n (%) 50 (2.0) 31 (1.8)
≧0.65, n (%) 63 (2.6) 62 (3.6)
Missing, n (%) 311 (12.7) 194 (11.2)
Exacerbations§ 0, n (%) 216 (8.8) 114 (6.6) 3.2
1, n (%) 608 (24.8) 306 (17.6)
2, n (%) 796 (32.5) 560 (32.3)
3, n (%) 








Acute OCS courses§ 0, n (%) 1051 (42.9) 700 (40.3) 1.4
1, n (%) 554 (22.6) 346 (19.9)
2, n (%) 379 (15.5) 272 (15.7)
3, n (%) 170 (6.9) 145 (8.4)
4, n (%) 111 (4.5) 80 (4.6)
≥5, n (%) 185 (7.6) 192 (11.1)
Antibiotics courses§ 0, n (%) 717 (29.3) 505 (29.1) 0.9
1, n (%) 825 (33.7) 557 (32.1)
2, n (%) 541 (22.1) 386 (22.2)
3, n (%) 215 (8.8) 171 (9.9)
4, n (%) 87 (3.6) 65 (3.7)
≥5, n (%) 65 (2.7) 51 (2.9)
GOLD group A, n (%) 358 (14.6) 175 (10.1) 1.7
B, n (%) 348 (14.2) 170 (9.8)
C, n (%) 689 (28.1) 575 (33.1)
D, n (%) 781 (31.9) 601 (34.6)
Missing, n (%) 274 (11.2) 214 (12.3)
FEV1% predicted in 2-year period <30, n (%) 84 (3.4) 92 (5.3) 0.4
30 <50, n (%) 513 (20.9) 385 (22.2)
50 <80, n (%) 1164 (47.5) 676 (39.0)
≧80, n (%) 319 (13.0) 205 (11.8)
Missing, n (%) 370 (15.1) 377 (21.7)
Note: §: Counts in a 1-year baseline period. 
Abbreviations: BMI, body mass index; FEV1, forced expiratory volume in 1 second; GOLD, Global Initiative for Chronic Obstructive Pulmonary Disease; IPT, inverse probability of 
treatment; LABA/LAMA, long-acting beta-agonist plus long-acting muscarinic antagonist; OCS, oral corticosteroids; SD, standard deviation; SMD, IPT weighted standardized mean 
difference.
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extrafine BDP/FF and LABA/LAMA. The results from 
assessment of effect modification of the modifier candi-
dates using the primary and secondary outcomes is shown 
in Table e4 as p-values of the interaction term in the 
adjusted outcome models corrected for multiple testing. 
In subgroup analyses, no indication that blood eosinophil 
count was predictive of the rate of exacerbations during 
follow-up in the extrafine BDP/FF group was found. 
However, LABA/LAMA tended to lose efficacy in redu-
cing exacerbations with increasing eosinophil count. In the 
Table 3 Number of Patients Who Improved, Remained Stable, or Worsened from 1-Year Baseline to the First Outcome Year
Unadjusted LABA/LAMA, N (%) Extrafine BDP/FF, N (%)
Outcome Improved Stable Worsened Improved Stable Worsened
Exacerbations 1425 (58.1) 450 (18.4) 575 (23.5) 1058 (61.0) 304 (17.5) 373 (21.5)
Acute OCS courses 928 (37.9) 868 (35.4) 654 (26.7) 693 (39.9) 529 (30.5) 513 (29.6)
Antibiotics courses 1221 (49.8) 765 (31.2) 464 (19.0) 858 (49.4) 591 (34.1) 286 (16.5)
Acute respiratory events 1430 (58.4) 374 (15.2) 646 (26.4) 1071 (61.7) 255 (14.7) 409 (23.6)
Hospitalizations 230 (9.4) 2092 (85.4) 128 (5.2) 186 (10.7) 1436 (82.8) 113 (6.5)
A&E attendances 92 (3.8) 2311 (94.3) 47 (1.9) 97 (5.6) 1585 (91.3) 53 (3.1)
IPT Weighted LABA/LAMA, N (%) Extrafine BDP/FF, N (%)
Outcome Improved Stable Worsened Improved Stable Worsened
Exacerbations 1278 (58.9) 378 (17.4) 514 (23.7) 1205 (59.8) 376 (18.7) 434 (21.5)
Acute OCS courses 829 (38.1) 736 (33.9) 604 (27.8) 792 (39.3) 661 (32.8) 563 (27.9)
Antibiotics 1088 (50.2) 671 (30.9) 411 (18.9) 991 (49.2) 685 (34.0) 339 (16.8)
Acute respiratory events 1264 (58.3) 326 (15.0) 579 (26.7) 1237 (61.4) 303 (15.0) 476 (23.6)
Hospitalizations 211 (9.7) 1840 (84.9) 118 (5.4) 205 (10.2) 1688 (83.7) 123 (6.1)
A&E attendances 81 (3.7) 2049 (94.5) 39 (1.8) 108 (5.4) 1847 (91.6) 61 (3.0)
Abbreviations: A&E, accident and emergency; LABA/LAMA, long-acting beta-agonist plus long-acting muscarinic antagonist; OCS, oral corticosteroids.
Figure 3 Model results, all patients. 
Abbreviations: Extrafine BDP/FF, extrafine beclometasone dipropionate/formoterol fumarate; LABA/LAMA, long-acting beta-agonist plus long-acting muscarinic antagonist; 
mMRC, Modified Medical Research Council Dyspnea Scale; OCS, oral corticosteroids.
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subgroup of patients that came from LAMA or LABA 
monotherapy, blood eosinophil count showed a clear 
trend (p=0.051) of comparative effectiveness based on 
the number of SABA inhalers used in favor of extrafine 
BDP/FF with increasing eosinophil count. See the Online 
Supplementary Materials for results of effect modification 
in the subgroup analyses (Figures e2–e3).
Discussion
This historical real-world observational study showed 
similar exacerbation reduction from the baseline to the 
first outcome year in patients who initiated extrafine 
BDP/FF and those who initiated LABA/LAMA from no 
maintenance or monotherapy. Stepping up to extrafine 
BDP/FF was not inferior to stepping up to double bronch-
odilation therapy in patients with a history of 
exacerbations.
Our non-inferiority finding is in agreement with 
another real-world study comparing LABA/LAMA to 
any ICS/LABA initiators.24 Our results are in contrast to 
the finding of superiority of indacaterol/glycopyrronium 
(LABA/LAMA) over fluticasone/salmeterol (ICS/LABA) 
in exacerbation reduction in the FLAME study.9 Our study 
population had a comparable exacerbation burden (≥2 in 
a 2-year baseline vs ≥1 in a 1-year period in the trial), but 
we compared different compounds. This might suggest 
that the extrafine particle size of BDP/FF needs to be 
taken into account when evaluating the choice between 
double bronchodilation therapy and ICS/LABA.
For all outcomes (rates of exacerbations, acute OCS 
courses, antibiotics courses, and acute respiratory events) 
non-inferiority of extrafine BDP/FF could be claimed with 
the exception of having an mMRC score ≥2 and time until 
a pneumonia infection. The number of pneumonia cases 
during follow-up was low (n = 15); four with BDP/FF and 
11 with LABA/LAMA. This could relate to the molecular 
characteristics of FF or to the extrafine BDP/FF formula-
tion increasing the volume of drug distribution within the 
bronchial tree. The pneumonia incidence rate was 0.25 
cases per 100 patient-years (in the IMPACT study there 
was an incidence rate of between 6–10 cases per 100 
patient-years10), resulting in low statistical power as well 
as the inability to check models for residual confounding. 
Similarly, for MRC dyspnoea scale the OR is 0.96. 
However, the 95% CI is wide, and its upper limit crosses 
the non-inferiority margin. The result is not unexpected as 
MRC scores are variably associated with patients’ percep-
tions of respiratory symptom burden or disease severity.25 
None of the candidate modifiers (blood eosinophil count, 
exacerbations, GOLD group, FEV1% predicted, other 
medication burden) significantly changed the comparative 
effectiveness. Although extrafine BDP/FF is licensed for 
patients with COPD and a FEV1% predicted below 50% 
and a history of repeated exacerbations,26 we did not find 
evidence that the comparative effectiveness was different 
depending on the FEV1% predicted and exacerbation rate 
in the one-year baseline period. Missing FEV1 data may 
have resulted in loss of power and dilution of any possible 
effect modification of baseline FEV1 on the outcomes after 
initiation of treatments.
We did not find a significant impact of difference of 
eosinophil count on the comparative effectiveness, despite 
a trend when comparing the two treatments in 
a subpopulation of patients stepping up from LAMA or 
LABA monotherapy, the patients the treatment guidelines8 
refer to. In addition, in these patients a trend in favor of 
extrafine BDP/FF on SABA reduction with increasing 
eosinophil count exists. The limited number of patients 
analyzed is preventing us reaching the conclusions pro-
vided by Suissa et al, who analyzed a population-based 
cohort of 12,366 initiators of LAMAs (mainly tiotropium) 
matched to 12,366 initiators of LABA-ICS.27 They found 
that initial treatment with ICS/LABAs was only more 
effective than with LAMAs in patients with high blood 
eosinophil counts.
We used the most recently recorded blood eosinophil 
count within five years. Almost 45% of the eosinophil 
counts were recorded within 6 months prior to the index 
date, 66% within one year, and only 16% were recorded 
more than two years earlier. Some studies on stability of 
blood eosinophil counts over time have shown that values 
remain reasonably stable over a period of two years.28,29 
Therefore, we do not think this has affected our results.
Our data indicate that treatment exposure lasted 1-year 
in approximately 38% of patients. It is a higher percentage 
in comparison to figures reported by Suissa et al, who 
found that 67% of patients in the LABA/LAMA group 
and 72% in the ICS/LABA group discontinued the treat-
ment after 3.3 months.24
The strengths of our study include the large cohort of 
patients from a real-world setting, representative of the 
UK population, making our results likely generalizable to 
the wider COPD population. Some limitations however 
also need consideration. The OPCRD dataset represents 
information collected for clinical and routine use rather 
than specifically for research purposes but reflects real- 
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world prescribing practices. However, extensive quality 
control and validity checks are conducted at practice 
level. Also, the study had limited power to detect differ-
ences in pneumonia events due to low incidence rates. 
Finally, we could only adjust for confounding by measured 
and considered baseline characteristics of the patients. 
Thus, we cannot guarantee that our results are unbiased; 
however, as the most important disease severity indicators 
were used for propensity score estimation, it is unlikely 
that any residual bias is large.
Conclusion
In summary, this observational study found that stepping 
up to extrafine BDP/FF from no maintenance or mono-
therapy was not inferior to stepping up to double bronch-
odilation therapy in patients with a history of COPD 
exacerbations. The study did not identify patient factors 
that relevantly modified the comparative effectiveness. 
Notably, the finding that the FEV1% predicted did not 
modify the comparative effectiveness calls for studies to 
explore the possibility to indicate extrafine BDP/FF for 
a broader target population. Overall, these real-world find-
ings confirm how extrafine ICS/LABA fits into mainte-
nance therapy of COPD patients at risk of exacerbations. 
Eosinophilia should be considered a continuum in thera-
peutic decision making; however, more studies are needed 
to better understand how blood eosinophil count interacts 
with exacerbation burden and treatment choice on exacer-
bation reduction in larger real-world cohorts.
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